Zyprexa 2.5 mg (Olanzapine)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition. Doses exceeding the general recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. 1. Adults 1) Schizophrenia (1) The recommended initial dose is 5∼10 mg of olanzapine once daily. (2) Maintenance treatment: It is difficult to provide a definitive answer as to how long treatment with this medicine should continue. Its efficacy was demonstrated in a placebo-controlled study in which patients with schizophrenia whose symptoms had stabilized after approximately 8 weeks of treatment with this medicine received maintenance treatment for 8 months at doses of 10∼20 mg daily. The need for maintenance treatment at an appropriate dose should be evaluated periodically. 2) Bipolar disorder (1) Treatment of manic and mixed episodes associated with bipolar I disorder The initial dose is 15 mg once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. (2) Prevention of recurrence in bipolar disorder The recommended initial dose is 10 mg once daily. For patients who have received this medicine to treat mania, continue the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, continue this medicine, together with adjunctive treatment for mood symptoms as clinically indicated (optimizing the required dose). 3) For schizophrenia, treatment of manic and mixed episodes associated with bipolar I disorder, and prevention of recurrence in bipolar disorder, the daily dose may be adjusted within the range of 5 mg to 20 mg based on the clinical condition. Doses above the recommended initial dose are recommended only after an appropriate clinical evaluation and should generally be increased at intervals of at least 24 hours. If treatment with this medicine is discontinued, the dose should be reduced gradually and cautiously. 4) Acute treatment of depressive episodes associated with bipolar I disorder Start treatment with 5 mg of olanzapine once daily, then increase to 10 mg once daily. Administer this medicine at bedtime and adjust the dose appropriately according to age and symptoms; do not exceed a daily dose of 20 mg. Since food does not affect drug absorption, this medicine may be taken with or without food. 2. Dosing in special populations 1) Older adults Starting at a dose of 5 mg or less daily may be considered when supported by sufficient clinical factors. 2) Patients with renal or hepatic impairment A low initial dose (5 mg) should be considered. In moderate hepatic impairment (cirrhosis, Child-Pugh class A or B), the initial dose is 5 mg and should be increased cautiously. 3) Patients with multiple factors that delay the metabolism of this medicine (female sex, older age, and nonsmoking status) may also be started at a lower dose. 3. Precautions (for orally disintegrating tablets only) This medicine is fragile. Remove it from the outer package by peeling off the foil backing of the blister to open it. Do not push the tablet through the foil when opening the blister. Immediately after opening the blister, remove the tablet with dry hands and place it directly in the mouth. The tablet disintegrates rapidly in saliva and may be swallowed with or without liquid.

This medication can cause serious side effects such as neuroleptic malignant syndrome. If symptoms such as high fever, muscle rigidity, or changes in mental state occur, use should be discontinued immediately. It is not recommended for the treatment of psychosis or behavioral disorders associated with dementia, especially in elderly patients, as it may increase mortality and the risk of cerebrovascular disease. Long-term use may result in movement disorders known as tardive dyskinesia, so dosage adjustment or discontinuation should be considered if symptoms emerge. This medication may cause metabolic side effects such as weight gain, elevated blood sugar, and dyslipidemia, thus regular health check-ups and monitoring are necessary. Sudden discontinuation can lead to withdrawal symptoms such as sweating, insomnia, and anxiety, so it is safer to taper off gradually. Caution is required for patients with impaired liver function, a history of seizures, or cardiovascular diseases when using this medication. Women who are pregnant or breastfeeding should consult a doctor before using it, as it may affect the fetus or newborn. This medication may cause drowsiness and dizziness, thus caution is necessary when driving or operating dangerous machinery. There may be interactions with other medications, so it is important to inform healthcare providers of any other medications being taken, especially not to use concurrently with epinephrine. Overdose may lead to serious side effects, so prescribed dosages must be adhered to and healthcare professionals should be informed immediately if any unusual symptoms arise. This medication should be kept out of reach of children and stored in a cool and dry place away from direct sunlight.

• High fever
• muscle rigidity
• changes in mental state
• irregular pulse
• changes in blood pressure
• tachycardia
• sweating
• arrhythmia
• elevated creatine phosphokinase
• myoglobinuria

This medication should be stored in a tightly closed container to protect it from air or moisture. It is advisable to maintain a storage temperature between 15 and 30 degrees Celsius. Storing it this way helps to preserve the medication's efficacy and safety.

Appearance

White round film-coated tablet

Package unit

Bottle - 100 tablets/bottle, PTP - 30 tablets/PTP [10 tablets/PTP x 3]